
Cybin Inc (HELP) Stock Forecast & Price Target
Cybin Inc (HELP) Analyst Ratings
Bulls say
Helus Pharma is a clinical-stage biotechnology company with a promising pipeline of innovative serotonin-targeting compounds for treating mental health disorders such as depression and anxiety. The company's ongoing Phase 3 trials and their recent positive results from their Phase 2 trial demonstrate their potential to address the limitations of current treatments and make a significant impact in the neuropsychiatry sector. With a recently strengthened executive team and clear regulatory guidance for psychedelic therapies, the company is well-positioned for success.
Bears say
Helus Pharma is a clinical-stage pharmaceutical company focused on developing neuroactive compounds targeting serotonin pathways to treat mental health conditions. Despite ongoing enrollment in the pivotal Phase 3 EMBRACE study for their lead compound HLP003 and positive Phase 2 data for HLP004 in generalized anxiety disorder, there are inherent risks in the biotechnology sector, and Helus may face challenges in accessing the necessary capital to complete development. Additionally, a recent underwritten offering and potential delays in launch timelines lead to a lowered price target of $70 per share, though the company's upcoming Phase 3 APPROACH top-line readout remains on track and has potential to validate their novel therapeutic approach.
This aggregate rating is based on analysts' research of Cybin Inc and is not a guaranteed prediction by Public.com or investment advice.
Cybin Inc (HELP) Analyst Forecast & Price Prediction
Start investing in Cybin Inc (HELP)
Order type
Buy in
Order amount
Est. shares
0 shares